Oral targeted therapies

被引：0
|
作者：
Etienne-Selloum, Nelly [1 ,2 ]
机构：
[1] Univ Strasbourg, Lab Bioimagerie & Pathol LBP Equipe Tumoral Signa, Fac Pharm, Unistra,CNRS,UMR 7021, 74 Route Rhin,CS 60024, F-67401 Illkirch Graffenstaden, France
[2] Ctr Lutte Canc Paul Strauss, Dept Pharm, 3 Rue Porte Hop, F-67000 Strasbourg, France
来源：
ACTUALITES PHARMACEUTIQUES | 2018年 / 57卷 / 578期
关键词：
angiogenesis; BCR/ABL; BRAF; EGFR; kinase inhibitor; MEK; targeted therapy;
D O I：
10.1016/j.actpha.2018.05.007
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Lack of selectivity associated with a low therapeutic index of cytotoxic drugs together with improved knowledge of the carcinogenesis mechanisms have led to the development of a new therapeutic strategy for cancer which is more targeted and theoretically less toxic. Anticancer targeted therapies can kill cancer cells more selectively by interfering with specific protein or process involved in cancer growth. These treatments have considerably improved survival and quality of life of patients, most of them being self-administered at home. (C) 2018 Elsevier Masson SAS. All rights reserved
引用
收藏
页码：13 / 18
页数：6
相关论文
共 50 条
  • [21] Targeted Therapies
    Loriot, Y.
    ONCOLOGIE, 2012, 14 (08) : 462 - 464
  • [22] Targeted therapies
    Loriot, Y.
    ONCOLOGIE, 2009, 11 (7-8) : 416 - 417
  • [23] Oral targeted therapies in non-small cell cancer - managing toxicities
    Alexander, Marliese
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 55 - 55
  • [24] Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
    Vigarios, Emmanuelle
    Epstein, Joel B.
    Sibaud, Vincent
    SUPPORTIVE CARE IN CANCER, 2017, 25 (05) : 1713 - 1739
  • [25] Review article: novel oral-targeted therapies in inflammatory bowel disease
    White, J. R.
    Phillips, F.
    Monaghan, T.
    Fateen, W.
    Samuel, S.
    Ghosh, S.
    Moran, G. W.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (12) : 1610 - 1622
  • [26] Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
    van der Kleij, M. B. A.
    Guchelaar, N. A. D.
    Meertens, M.
    Giraud, E. L.
    Bleckman, R. F.
    Imholz, A. L. T.
    Vulink, A.
    Otten, H-M. M. B.
    Smilde, T. J.
    Los, M.
    Fiebrich, H-B.
    Hamberg, P.
    Lubberman, F. J. E.
    Koolen, S. L.
    Gelderblom, H.
    Reyners, A. K. L.
    Van Erp, N. P.
    Mathijssen, R. H.
    Huitema, A. D. R.
    Steeghs, N.
    ANNALS OF ONCOLOGY, 2023, 34 : S490 - S490
  • [27] Initial Patterns of Care With Oral Targeted Therapies for Patients With Renal Cell Carcinoma
    Filson, Christopher P.
    Redman, Bruce G.
    Dunn, Rodney L.
    Miller, David C.
    UROLOGY, 2011, 77 (04) : 825 - U366
  • [28] Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine
    Groenland, Stefanie L.
    Mathijssen, Ron H. J.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    Steeghs, Neeltje
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (09) : 1309 - 1318
  • [29] Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine
    Stefanie L. Groenland
    Ron H. J. Mathijssen
    Jos H. Beijnen
    Alwin D. R. Huitema
    Neeltje Steeghs
    European Journal of Clinical Pharmacology, 2019, 75 : 1309 - 1318
  • [30] Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
    Emmanuelle Vigarios
    Joel B. Epstein
    Vincent Sibaud
    Supportive Care in Cancer, 2017, 25 : 1713 - 1739
12345